TY - JOUR
T1 - Economic value of dengue vaccine in Thailand
AU - Lee, Bruce Y.
AU - Connor, Diana L.
AU - Kitchen, Sarah B.
AU - Bacon, Kristina M.
AU - Shah, Mirat
AU - Brown, Shawn T.
AU - Bailey, Rachel R.
AU - Laosiritaworn, Yongjua
AU - Burke, Donald S.
AU - Cummings, Derek A.T.
PY - 2011/5
Y1 - 2011/5
N2 - With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1x per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3x per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.
AB - With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1x per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3x per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.
UR - http://www.scopus.com/inward/record.url?scp=79958715836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958715836&partnerID=8YFLogxK
U2 - 10.4269/ajtmh.2011.10-0624
DO - 10.4269/ajtmh.2011.10-0624
M3 - Article
C2 - 21540387
AN - SCOPUS:79958715836
SN - 0002-9637
VL - 84
SP - 764
EP - 772
JO - American Journal of Tropical Medicine and Hygiene
JF - American Journal of Tropical Medicine and Hygiene
IS - 5
ER -